Dominique Higgins

Dominique Higgins

Auto-generated profile, based on publicly available information

Dominique Higgins

Department of Neurosurgery, University of North Carolina, Chapel Hill, North Carolina

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DHDominique M. O. Higgins
Dominique M. O. Higgins
MCMaisel Caliva
Maisel Caliva
MSMark Schroeder
Mark Schroeder
BCBrett Carlson
Brett Carlson
PUPavan S. Upadhyayula
Pavan S. Upadhyayula
JHJohn R. Henley
John R. Henley
Background: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults, with a median survival of approximately 15 months. Semaphorin 3A (Sema3A), known for its axon guidance and antiangiogenic properties, has been implicated in GBM growth. We hypothesized that Sema3A directly inhibits brain tumor stem cell (BTSC) proliferation and drives invasion via Neuropilin 1 (Nrp1) and Plexin A1 (PlxnA1) receptors. Methods: GBM BTSC cell lines were assayed by immunostaining and PCR for levels of Semaphorin 3A (Sema3A) and its receptors Nrp1 and PlxnA1. Quantitative BrdU, cell cycle and propidium iodide labeling assays were performed following exogenous Sema3A treatment. Quantitative functional 2-D and 3-D invasion assays along with shRNA lentiviral knockdown of Nrp1 and PlxnA1 are also shown. In vivo flank studies comparing tumor growth of knockdown versus control BTSCs were performed. Statistics were performed using GraphPad Prism v7. Results: Immunostaining and PCR analysis revealed that BTSCs highly express Sema3A and its receptors Nrp1 and PlxnA1, with expression of Nrp1 in the CD133 positive BTSCs, and absence in differentiated tumor cells. Treatment with exogenous Sema3A in quantitative BrdU, cell cycle, and propidium iodide labeling assays demonstrated that Sema3A significantly inhibited BTSC proliferation without inducing cell death. Quantitative functional 2-D and 3-D invasion assays showed that treatment with Sema3A resulted in increased invasion. Using shRNA lentiviruses, knockdown of either NRP1 or PlxnA1 receptors abrogated Sema3A antiproliferative and pro-invasive effects. Interestingly, loss of the receptors mimicked Sema3A effects, inhibiting BTSC proliferation and driving invasion. Furthermore, in vivo studies comparing tumor growth of knockdown and control infected BTSCs implanted into the flanks of nude mice confirmed the decrease in proliferation with receptor KD. Conclusions: These findings demonstrate the importance of Sema3A signaling in GBM BTSC proliferation and invasion, and its potential as a therapeutic target.

25 March 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
HKHumeyra Kaanoglu
Humeyra Kaanoglu
AAAdebimpe Adefolaju
Adebimpe Adefolaju
CFCasey Fraley
Casey Fraley
MSMariah Shobande
Mariah Shobande
RDRajaneekar Dasari
Rajaneekar Dasari
ASAndrew Satterlee
Andrew Satterlee
Glioblastoma (GBM) is the most common type of malignant central nervous system tumor, and more than 300,000 people are diagnosed with GBM worldwide annually. Based on its recognition as damage by nucleotide excision repair, we now repurpose the DNA labeling agent 5-ethynyl-2′-deoxyuridine (EdU) as a treatment for GBM. We tested the efficacy of EdU in several different model systems, including not only GBM cell lines in in vitro cell culture and in vivo orthotopic mouse models of GBM, but also against living, uncultured tumor tissues of patients with GBM grown within our organotypic brain slice culture (OBSC) ex vivo platform. When compared with the standard-of-care drug temozolomide (TMZ) in in vitro GBM cell survival assays, EdU displayed ED50 values orders of magnitude lower than those of TMZ in all five GBM tumor lines tested. Against two in vivo orthotopic brain tumor models, EdU significantly extended survival relative to controls. EdU efficacy against a panel of patient GBMs largely correlated with the clinical Ki-67 status of each tumor, save for one tumor that remained unresponsive to treatment with both EdU and TMZ. Overall, these data suggest that (i) EdU has potential to be repurposed as an anticancer therapeutic and is especially adept at killing rapidly proliferating cells with low off-target toxicity; (ii) the OBSC platform can measure nuanced differences in efficacy of experimental therapeutics on heterogeneous patient tumor tissues; and (iii) OBSCs can continue to help identify potential responders and nonresponders to EdU treatment via functional precision testing of patient tumors ex vivo.

11 February 2023 in World Neurosurgery
Verified
Journal Article
Closed access
TETiffany Eatz
Tiffany Eatz
ALAdam Levy
Adam Levy
MMMartín Merenzon
Martín Merenzon
LBLauren Bystrom
Lauren Bystrom
KBKatherine Berry
Katherine Berry
Michael E. IvanMichael E. Ivan
Michael E. Ivan

18 November 2024 in Neurosurgery
Verified
Journal Article
Closed access
BLBoyi Li
Boyi Li
CSColette J Shen
Colette J Shen
DHDominique Higgins
Dominique Higgins

1 August 2025
Verified
Other
Open access
HKHumeyra Kaanoglu
Humeyra Kaanoglu
AAAdebimpe Adefolaju
Adebimpe Adefolaju
CFCasey Fraley
Casey Fraley
MSMariah Shobande
Mariah Shobande
RDRajaneekar Dasari
Rajaneekar Dasari
ASAndrew Satterlee
Andrew Satterlee
Figure S1: Illustration of the proposed futile cycle induced by the incorporation of EdU by DNA polymerases and removal of it by excision repair. EdU gets incorporated into the genome of highly proliferative GBM cells in the brain. Then, EdU-containing DNA is recognized and removed by nucleotide excision repair, leaving the DNA gap to be filled in. During the resynthesis, EdU reincorporates into this repair patch and the futile cycle repeats, leading to apoptosis and thus, suppression of the growth of GBM tumor.

22 October 2025 in bioRxiv
Verified
Preprint
Open access
HKHumeyra Kaanoglu
Humeyra Kaanoglu
YAYasemin Kubra Akyel
Yasemin Kubra Akyel
AAAdebimpe Adefolaju
Adebimpe Adefolaju
AVAlain Valdivia
Alain Valdivia
DHDominique Higgins
Dominique Higgins
ASAziz None Sancar
Aziz None Sancar
Glioblastoma (GBM) is the most aggressive malignant primary brain tumor in adults, with incidence peaking in later life. It is commonly treated with surgery followed by administration of ionizing radiation and the DNA alkylating agent temozolomide (TMZ). Even though this regimen confers some progression-free survival, there is essentially no cure with the median survival with the standard of care being about 12 months. Currently, several alternative approaches are being developed to improve upon this outcome. We have already shown EdU alone effectively treats GBM, and we now study efficacy of TMZ+EdU combination therapy. TMZ+EdU significantly improves antitumor efficacy compared to either single-agent therapy against GBM cell lines in vitro , against three different orthotopic GBM xenograft models, and against passage-zero patient GBM tumor tissues engrafted within an organotypic brain slice culture (OBSC)-based platform. Together, these data suggest that EdU could be effective alongside standard of care TMZ in patients with GBM. STATEMENT OF SIGNIFICANCE (50-WORD): By simultaneously engaging distinct DNA repair pathways, combination of TMZ and EdU produced unprecedented survival benefits and synergistic effects in preclinical GBM models, offering a promising new avenue in the treatment of GBM.